Peripheral neuropathy — distal weakness and sensory loss
Caused by inhibition of neuropathy target esterase (NTE)
Therapeutic Considerations
Atropine dosing philosophy
Doses far exceeding standard ACLS are required
Standard ACLS dose (0.5–1 mg) is subtherapeutic in significant poisoning
Cumulative doses of 40–100 mg in the first 24 hours reported in severe cases
Endpoint is pulmonary — clear lungs on auscultation
Pupil size is NOT a reliable endpoint — miosis may persist despite adequate treatment
Atropine maintenance infusion after loading
Prevents recurrent bronchorrhea from ongoing acetylcholine accumulation
Minimum 48 hours of continued therapy recommended
Pralidoxime controversy
High-dose vs. low-dose regimens
High-dose (2 g loading + 1 g/hr) showed survival benefit in RCTs from Sri Lanka
WHO recommends standard 1 g loading + 0.5 g/hr in resource-limited settings
Agent-specific limitations
Soman — ages within minutes, pralidoxime has minimal benefit
Parathion and fenthion — aging slower; pralidoxime most effective
Carbamates — spontaneous reactivation; pralidoxime less critical
AHA 2023 guidance
Pralidoxime supported as adjunct to atropine (Class IIa)
Give early before irreversible aging occurs
Succinylcholine avoidance
Pseudocholinesterase (plasma cholinesterase) is inhibited by organophosphates
Succinylcholine is metabolized by pseudocholinesterase
Paralysis may persist for hours to days instead of minutes
Rocuronium 1.2 mg/kg is the safe alternative
Patient Discharge Instructions
copy discharge instructions
Discharge instructions for cholinergic toxicity
What happened to you
You were poisoned by a chemical that overstimulates nerves throughout your body
This caused excessive secretions, muscle twitching, and difficulty breathing
You received antidote medications to reverse the poison's effects
Medications
Take all prescribed medications exactly as directed
Do not resume cholinesterase inhibitor medications (donepezil, rivastigmine, pyridostigmine) without your doctor's approval
Warning signs — return to emergency immediately
New or returning difficulty breathing or shortness of breath
Excessive drooling or secretions returning
Inability to lift your head off the bed or new muscle weakness
Blurred vision or pinpoint pupils returning
Confusion, agitation, or loss of consciousness
Muscle twitching or uncontrolled movements
Vomiting, severe diarrhea, or abdominal cramping
Intermediate syndrome warning
A delayed complication called intermediate syndrome can occur 1–4 days after poisoning
Signs include severe weakness of arms, legs, and difficulty breathing
Return immediately if you develop new weakness even days after feeling better
Delayed neuropathy warning
In some cases, nerve damage can develop 2–3 weeks after exposure
Signs include numbness, tingling, or weakness in hands and feet
Report any new sensory or motor changes to your doctor
Activity restrictions
Avoid strenuous physical activity for at least 1 week
Do not operate machinery or drive until fully recovered and cleared by a physician
Do not handle pesticides or chemicals related to your exposure
Occupational safety
If exposure was work-related, report to occupational health
Workplace safety assessment before returning to work
Ensure proper PPE is available and fitted before resuming work
Follow-up
Follow-up appointment within 1–2 days for mild exposures
Repeat cholinesterase levels may be ordered to monitor recovery
Mental health
If this poisoning was intentional, please attend all scheduled mental health appointments
Crisis resources: 988 Suicide and Crisis Lifeline (call or text 988)
References
Guidelines and key sources
American Heart Association 2023 Focused Update
Lavonas EJ, et al. 2023 AHA Focused Update on Management of Patients With Cardiac Arrest or Life-Threatening Toxicity Due to Poisoning. Circulation. 2023
Class I recommendation for atropine as first-line agent
Class IIa recommendation for pralidoxime as adjunct
Benzodiazepines Class I for seizure management
Succinylcholine avoidance explicitly recommended
American Heart Association 2025 Guidelines
Cao D, et al. Part 10: Adult and Pediatric Special Circumstances of Resuscitation. Circulation. 2025
Updated guidance on toxicological cardiac arrest management
Landmark trials and clinical evidence
Eddleston M, et al. Management of Acute Organophosphorus Pesticide Poisoning. Lancet. 2008
Systematic review of atropine dosing and outcomes
Established high-dose pralidoxime regimen data
Aman S, et al. Management of Organophosphorus Poisoning: Standard Treatment and Beyond. Critical Care Clinics. 2021
Comprehensive review of treatment controversies
Pralidoxime high-dose vs. low-dose RCT data
Reference texts
Henretig FM, Kirk MA, McKay CA. Hazardous Chemical Emergencies and Poisonings. NEJM. 2019
Kales SN, Christiani DC. Acute Chemical Emergencies. NEJM. 2004
Pediatric specific
Chung S, et al. Chemical-Biological Terrorism and Its Impact on Children. Pediatrics. 2020
AAP guidance on pediatric cholinergic toxidrome management
Biochemical monitoring
Sepahi S, et al. Biochemical Responses as Biomarkers of Organophosphate and Carbamate Intoxication. Journal of Biochemical and Molecular Toxicology. 2023
Systematic review of cholinesterase assay clinical utility
SymptomDx is an educational tool for medical professionals. It does not replace clinical judgment. Verify all clinical data and drug dosages with authoritative sources.